Cargando…

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

Metronomic chemotherapy refers to the administration of chemotherapy at low, nontoxic doses on a frequent schedule with no prolonged breaks. The aim of the study is to rationally develop a CPT-11 metronomic regimen in preclinical settings of colon cancer. In vitro cell proliferation, apoptosis and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bocci, G, Falcone, A, Fioravanti, A, Orlandi, P, Di Paolo, A, Fanelli, G, Viacava, P, Naccarato, A G, Kerbel, R S, Danesi, R, Del Tacca, M, Allegrini, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391121/ https://www.ncbi.nlm.nih.gov/pubmed/18443598 http://dx.doi.org/10.1038/sj.bjc.6604352

Ejemplares similares

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
por: Awasthi, Niranjan, et al.
Publicado: (2022)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Antiangiogenic activity of aplidine, a new agent of marine origin
por: Taraboletti, G, et al.
Publicado: (2004)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan
por: Calvet, L, et al.
Publicado: (2004)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
por: Morbidelli, L, et al.
Publicado: (2003)

Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016)

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma
por: Granda, T G, et al.
Publicado: (2002)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

The pharmacological bases of the antiangiogenic activity of paclitaxel
por: Bocci, Guido, et al.
Publicado: (2013)

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft
por: Petrangolini, G, et al.
Publicado: (2004)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
por: Wilson, S, et al.
Publicado: (2015)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening
por: El-Zohairy, Mariam A., et al.
Publicado: (2021)

Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?
por: Günther, M, et al.
Publicado: (2008)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Ginger as an anticolorectal cancer spice: A systematic review of in vitro to clinical evidence
por: Nachvak, Seyed Mostafa, et al.
Publicado: (2022)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005)

Anticolorectal Cancer Effects of AUCAN: Effects to Suppress Proliferation, Metastasis, and Invasion of Tumor Cells
por: Xiong, Liu-Lin, et al.
Publicado: (2020)

Establishment of In Vitro and In Vivo Anticolorectal Cancer Efficacy of Lithocholic Acid-Based Imidazolium Salts
por: Sawicka, Diana, et al.
Publicado: (2022)

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
por: Yashiro, M, et al.
Publicado: (2013)

Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1
por: Xu, Li, et al.
Publicado: (2017)

Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial
por: Peyrl, Andreas, et al.
Publicado: (2023)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6jjm82vrd2hjlafs615mvi209p